In colorectal cancer, RUNX2 influences MAP kinase signaling via regulation of multiple RTKs, and its absence, can lead to resistance against MEK inhibitors along with its cofactor CBFB [75]. This evidence concerns the gene MAP2K7 and colorectal cancer.